Skip to Content
Merck
  • Central nervous system vasculitis caused by propylthiouracil therapy: a case report and literature review.

Central nervous system vasculitis caused by propylthiouracil therapy: a case report and literature review.

Thyroid : official journal of the American Thyroid Association (2005-02-03)
C Vanek, M H Samuels
ABSTRACT

Antineutrophil cytoplasmic antibodies (ANCA) are associated with vasculitis, including vasculitis induced by drugs such as the thionamides. The affected organ systems in thionamide-induced vasculitis have been primarily renal, musculoskeletal, and dermatologic. We describe the first case of thionamide-induced central nervous system vasculitis presenting as confusion, with complete resolution after discontinuation of propylthiouracil. We review the literature and summarize 42 additional cases of thionamide-induced ANCA-positive vasculitis since 1992. Propylthiouracil was responsible in 93% of cases and the predominant ANCA pattern on immunofluorescent staining was perinuclear (p-ANCA). Clinical improvement occurred after drug discontinuation in 93%, steroid therapy was used in some cases. The mean duration of treatment with thionamides was 35 months prior to presentation. Long-term medical treatment with thionamides for hyperthyroidism may increase the risk of this severe side effect.

MATERIALS
Product Number
Brand
Product Description

Propylthiouracil, European Pharmacopoeia (EP) Reference Standard
Supelco
6-Propyl-2-thiouracil, VETRANAL®, analytical standard
Sigma-Aldrich
6-Propyl-2-thiouracil, enzyme inhibitor